Analysts at StockNews.com initiated coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Get Rating) in a research report issued on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Shares of NASDAQ CRBP opened at $0.30 on Monday. The firm’s 50-day simple moving average is $0.29 and its 200 day simple moving average is $0.39. The company has a market cap of $37.65 million, a price-to-earnings ratio of -0.91 and a beta of 2.01. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.22. Corbus Pharmaceuticals has a 12-month low of $0.21 and a 12-month high of $1.73.
Corbus Pharmaceuticals (NASDAQ:CRBP – Get Rating) last issued its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. On average, equities analysts expect that Corbus Pharmaceuticals will post -0.24 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. ETF Managers Group LLC lifted its position in Corbus Pharmaceuticals by 0.3% during the 4th quarter. ETF Managers Group LLC now owns 14,138,998 shares of the biopharmaceutical company’s stock worth $8,534,000 after buying an additional 37,487 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Corbus Pharmaceuticals by 1.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,070,006 shares of the biopharmaceutical company’s stock worth $2,506,000 after purchasing an additional 69,769 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Corbus Pharmaceuticals by 371.0% during the 1st quarter. Renaissance Technologies LLC now owns 1,157,191 shares of the biopharmaceutical company’s stock worth $615,000 after purchasing an additional 911,491 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Corbus Pharmaceuticals during the 1st quarter worth about $275,000. Finally, Davy Global Fund Management Ltd raised its holdings in Corbus Pharmaceuticals by 36.6% during the 1st quarter. Davy Global Fund Management Ltd now owns 435,285 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 116,617 shares during the last quarter. Institutional investors and hedge funds own 35.61% of the company’s stock.
Corbus Pharmaceuticals Company Profile (Get Rating)
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases.
Featured Articles
Want More Great Investing Ideas?
Receive News & Ratings for Corbus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
